Evolent Health, Inc. (NYSE:EVH) Receives Consensus Rating of “Buy” from Brokerages

Shares of Evolent Health, Inc. (NYSE:EVH) have been assigned a consensus rating of “Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $17.92.

Several equities research analysts recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price objective on shares of Evolent Health in a research report on Friday, February 14th. Oppenheimer cut their price target on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of Evolent Health in a report on Wednesday, February 12th. BTIG Research decreased their price objective on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, December 3rd. Finally, Canaccord Genuity Group decreased their price target on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd.

Institutional Investors Weigh In On Evolent Health

A number of large investors have recently bought and sold shares of the stock. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Evolent Health during the fourth quarter valued at about $26,000. R Squared Ltd purchased a new stake in shares of Evolent Health during the 4th quarter valued at $31,000. AlphaQuest LLC raised its stake in shares of Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock worth $34,000 after purchasing an additional 3,031 shares during the period. Covestor Ltd boosted its holdings in shares of Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after buying an additional 826 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares during the period.

Evolent Health Stock Performance

Shares of NYSE:EVH opened at $10.09 on Friday. The business has a 50-day moving average price of $10.82 and a two-hundred day moving average price of $19.04. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $1.18 billion, a P/E ratio of -11.09 and a beta of 1.45. Evolent Health has a 1-year low of $9.45 and a 1-year high of $35.00.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.